Protalix Biotherapeutics Company Profile (NYSEMKT:PLX)

About Protalix Biotherapeutics

Protalix Biotherapeutics logoProtalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system, ProCellEx. Using its ProCellEx system, the Company is developing a pipeline of biosimilar or generic versions of recombinant therapeutic proteins based on its plant cell-based expression technology, which focuses pharmaceutical markets and that rely upon known biological mechanisms of action. ProCellEx protein expression system consists of a set of technologies and capabilities for the development of recombinant proteins, including advanced genetic engineering technology and plant cell-based protein expression methods. Its ProCellEx protein expression system is built on flexible custom-designed bioreactors made of polyethylene and optimized for the development of complex proteins in plant cell cultures. In June 2010, it had completed the preliminary phase I clinical trial of PRX-105.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NYSEMKT
  • Symbol: PLX
  • CUSIP:
Key Metrics:
  • Previous Close: $1.08
  • 50 Day Moving Average: $0.67
  • 200 Day Moving Average: $0.55
  • 52-Week Range: $0.26 - $1.13
  • Trailing P/E Ratio: 2.33
  • Foreward P/E Ratio: -4.00
  • P/E Growth: -0.12
  • Market Cap: $107.81M
  • Outstanding Shares: 99,821,000
  • Beta: 0.95
Additional Links:
Companies Related to Protalix Biotherapeutics:

Analyst Ratings

Consensus Ratings for Protalix Biotherapeutics (NYSEMKT:PLX) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $1.77

Analysts' Ratings History for Protalix Biotherapeutics (NYSEMKT:PLX)
Show:
DateFirmActionRatingPrice TargetDetails
12/15/2016MackieReiterated RatingBuy$1.00View Rating Details
9/6/2016Jefferies Group LLCLower Price TargetBuy$1.75 -> $0.80View Rating Details
7/11/2016Rodman & RenshawReiterated RatingBuyView Rating Details
(Data available from 2/21/2015 forward)

Earnings

Earnings History for Protalix Biotherapeutics (NYSEMKT:PLX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2016Q2 16($0.08)($0.11)$1.34 million$1.77 millionViewN/AView Earnings Details
3/8/2016Q415($0.29)$3.50 million$4.40 millionViewN/AView Earnings Details
11/10/2015Q3 15($0.08)($0.04)ViewN/AView Earnings Details
8/11/2015Q215($0.08)($0.05)ViewN/AView Earnings Details
5/7/2015Q1 15($0.08)($0.06)ViewN/AView Earnings Details
8/15/2014($0.07)($0.07)ViewN/AView Earnings Details
5/22/2014($0.07)($0.08)ViewN/AView Earnings Details
3/13/2014Q413($0.02)($0.12)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Protalix Biotherapeutics (NYSEMKT:PLX)
Current Year EPS Consensus Estimate: $-0.38 EPS
Next Year EPS Consensus Estimate: $-0.27 EPS

Dividends

Dividend History for Protalix Biotherapeutics (NYSEMKT:PLX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Protalix Biotherapeutics (NYSEMKT:PLX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/2/2016Camber Capital Management LlcMajor ShareholderSell2,500,000$0.32$800,000.00View SEC Filing  
12/14/2015Yossi MaimonCFOBuy10,000$0.78$7,800.00View SEC Filing  
10/19/2015Camber Capital Management LlcMajor ShareholderBuy4,000,423$1.00$4,000,423.00View SEC Filing  
8/15/2013Alfred AkirovDirectorSell112,330$5.05$567,266.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Protalix Biotherapeutics (NYSEMKT:PLX)
DateHeadline
4-traders.com logoProtalix BioTherapeutics : Announces Record Date for the 2017 Annual Meeting of Stockholders (NYSEMKT:PLX)
www.4-traders.com - February 20 at 9:26 AM
News IconO'Connor fund owns 9.5% of Protalix Biotherapeutics (NYSEMKT:PLX)
www.globes.co.il - February 19 at 9:24 AM
News IconProtalix Biotherapeutics Inc (NYSEMKT:PLX): Our Members Made 45% Quick Money After Buying at $1.01 This Week (NYSEMKT:PLX)
www.marketnewscall.com - February 19 at 9:24 AM
News IconOverbuying Stock in the Spotlight: Protalix Biotherapeutics Inc (NYSEMKT:PLX) - Post Registrar (NYSEMKT:PLX)
postregistrar.com - February 17 at 5:44 PM
News IconProtalix BioTherapeutics, Inc. (:PLX) EPS Projections in Focus ... - Rockville Register (NYSEMKT:PLX)
rockvilleregister.com - February 17 at 5:44 PM
marketexclusive.com logoProtalix BioTherapeutics, Inc. (NYSEMKT:PLX) Files An 8-K Regulation FD Disclosure (NYSEMKT:PLX)
marketexclusive.com - February 17 at 5:43 PM
4-traders.com logoPROTALIX BIOTHERAPEUTICS, INC. : Regulation FD Disclosure (form 8-K) (NYSEMKT:PLX)
www.4-traders.com - February 16 at 6:52 PM
biz.yahoo.com logoPROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure (NYSEMKT:PLX)
biz.yahoo.com - February 16 at 6:52 PM
marketexclusive.com logoProtalix BioTherapeutics, Inc. (NYSEMKT:PLX) Files An 8-K Shareholder Director Nominations (NYSEMKT:PLX)
marketexclusive.com - February 15 at 4:35 AM
us.rd.yahoo.com logoProtalix BioTherapeutics Announces Record Date for the 2017 Annual Meeting of Stockholders (NYSEMKT:PLX)
us.rd.yahoo.com - February 14 at 11:33 PM
News IconCan We Learn Anything From The Technical Chart of Protalix BioTherapeutics, Inc. (PLX)? - NY Stock News (NYSEMKT:PLX)
nystocknews.com - February 14 at 11:33 PM
globenewswire.com logoProtalix BioTherapeutics Announces Record Date for the 2017 Annual Meeting of Stockholders - GlobeNewswire (press release) (NYSEMKT:PLX)
globenewswire.com - February 14 at 11:33 PM
News IconAn Opportunity To Get In To Protalix Biotherapeutics Inc (NYSEMKT:PLX) Ahead Of Wider Market Awareness - Insider Financial (NYSEMKT:PLX)
www.insiderfinancial.com - February 14 at 11:33 PM
globenewswire.com logoProtalix BioTherapeutics to Participate in the 13th Annual WORLDSymposium™ 2017 - GlobeNewswire (press release) (NYSEMKT:PLX)
www.globenewswire.com - February 14 at 4:21 AM
seekingalpha.com logoProtalix continues up move, shares ahead 27% - Seeking Alpha (NYSEMKT:PLX)
seekingalpha.com - February 14 at 4:21 AM
finanznachrichten.de logoGainers & Losers Of The Day: ZSAN, PLSE, XOMA, SAGE, CBIO... (NYSEMKT:PLX)
www.finanznachrichten.de - February 13 at 11:19 PM
us.rd.yahoo.com logoProtalix BioTherapeutics to Participate in the 13th Annual WORLDSymposium™ 2017 (NYSEMKT:PLX)
us.rd.yahoo.com - February 13 at 11:19 PM
us.rd.yahoo.com logo8:42 am Protalix BioTherapeutics outperforming ahead of the open after previewing its presentations at this week's Annual WORLDSymposium (2/13-2/17) (NYSEMKT:PLX)
us.rd.yahoo.com - February 13 at 11:19 PM
globenewswire.com logoProtalix BioTherapeutics to Participate in the 13th Annual ... - GlobeNewswire (press release) (NYSEMKT:PLX)
globenewswire.com - February 13 at 9:14 AM
News IconRisk Analysis of Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) - The Oracle Examiner (NYSEMKT:PLX)
oracleexaminer.com - February 10 at 8:31 PM
News IconOverbuying Stock in Spotlight: Protalix Biotherapeutics Inc ... - Post Registrar (NYSEMKT:PLX)
postregistrar.com - February 10 at 2:36 AM
News IconOverbuying Stock in the Spotlight: Protalix Biotherapeutics Inc ... - Post Registrar (NYSEMKT:PLX)
postregistrar.com - February 8 at 2:19 AM
News IconProtalix BioTherapeutics Inc PLX Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NYSEMKT:PLX)
www.bioportfolio.com - February 7 at 9:19 PM
News IconProtalix BioTherapeutics (NYSE:PLX)- Stocks Cheering Investors with Mouthwatering Facts: Calithera Biosciences ... - Street Wise Report (press release) (blog) (NYSEMKT:PLX)
streetwisereport.com - February 6 at 9:01 AM
News IconProtalix BioTherapeutics, Inc. (AMEX:PLX) closed with a change of 17.19% - The Newburgh Press (NYSEMKT:PLX)
newburghpress.com - February 4 at 7:19 PM
News IconProtalix Biotherapeutics (PLX) Stock: Here's Why It's Up! | CNA ... - CNA Finance (press release) (NYSEMKT:PLX)
cnafinance.com - February 4 at 7:19 PM
News IconNewsworthy Wonder Stock: Penny Stock Investors Looking at Protalix BioTherapeutics, Inc. (:PLX) - Nelson Research (NYSEMKT:PLX)
nelsonobserver.com - February 1 at 1:40 AM
News IconStock ready to Pivot? Focus on Shares of Protalix BioTherapeutics ... - Prospect Journal (NYSEMKT:PLX)
prospectjournal.com - January 31 at 8:40 PM
News IconInvestor's Watch List: Rennova Health, Inc. (NASDAQ:RNVA), Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) - The Newburgh Press (NYSEMKT:PLX)
newburghpress.com - January 31 at 8:40 PM
zacks.com logoProtalix BioTherapeutics (PLX) Jumps: Stock Rises by 11.7% (NYSEMKT:PLX)
www.zacks.com - January 30 at 8:28 AM
streetinsider.com logoKnight Therapeutics Acquires 6.2M Shares of Protalix ... - StreetInsider.com (NYSEMKT:PLX)
www.streetinsider.com - January 30 at 12:44 AM
smarteranalyst.com logoProtalix Biotherapeutics Inc (PLX): Here Why Shares Surged 10% - Smarter Analyst (NYSEMKT:PLX)
www.smarteranalyst.com - January 28 at 5:42 AM
News IconTokio Marine Asset Management Co. Ltd. Cuts Stake in McKesson Corporation (MCK) (NYSEMKT:PLX)
onemma.net - January 27 at 1:02 AM
News IconMcKesson acquires CoverMyMeds for $1.1B (NYSEMKT:PLX)
myhealthbowl.com - January 27 at 1:02 AM
News IconFeatured Stock for Investors: Protalix BioTherapeutics, Inc ... - HugoPress (NYSEMKT:PLX)
hugopress.com - January 26 at 1:07 AM
News IconShares in View: Protalix BioTherapeutics Inc. (PLX) - Sherwood Daily (NYSEMKT:PLX)
sherwooddaily.com - January 26 at 1:07 AM
News IconTechnical Toolbox: Investor Focus on Protalix BioTherapeutics Inc. (PLX) - Sherwood Daily (NYSEMKT:PLX)
sherwooddaily.com - January 24 at 8:04 PM
News IconTop Stock With Upside & Growth Potential: Protalix BioTherapeutics ... - Prospect Journal (NYSEMKT:PLX)
prospectjournal.com - January 24 at 8:33 AM
News IconMarket Review: Indicator Watch for Protalix BioTherapeutics Inc. (PLX) - Sherwood Daily (NYSEMKT:PLX)
sherwooddaily.com - January 24 at 8:33 AM
News IconAre Institutions Trimming Down Their Positions In Protalix BioTherapeutics, Inc. (:PLX) - Wall Street Beacon (NYSEMKT:PLX)
wsbeacon.com - January 19 at 12:52 AM
News IconTrading Roundup: Checking Technicals for Protalix BioTherapeutics Inc. (PLX) - Sherwood Daily (NYSEMKT:PLX)
sherwooddaily.com - January 18 at 12:38 AM
News IconSmall Cap Concentration on Protalix BioTherapeutics, Inc. (:PLX) - Prospect Journal (NYSEMKT:PLX)
prospectjournal.com - January 18 at 12:38 AM
News IconMarkets End Mostly Higher, How Did This Stock Fare: Protalix BioTherapeutics, Inc. (:PLX) - Wall Street Beacon (NYSEMKT:PLX)
wsbeacon.com - January 15 at 12:22 AM
News IconBargain or Bait? Stock Update on Protalix BioTherapeutics, Inc. (:PLX) - Prospect Journal (NYSEMKT:PLX)
prospectjournal.com - January 14 at 1:33 AM
News IconInvestors Keen on a Bargain are Looking at Protalix BioTherapeutics, Inc. (:PLX) - Prospect Journal (NYSEMKT:PLX)
prospectjournal.com - January 12 at 12:58 AM
News IconGrowth Story Unfolding for Protalix BioTherapeutics, Inc. (:PLX) - Prospect Journal (NYSEMKT:PLX)
prospectjournal.com - January 9 at 7:56 PM
streetinsider.com logoProtalix BioTherapeutics (PLX) Issues 2016 Review, 2017 Outlook - StreetInsider.com (NYSEMKT:PLX)
www.streetinsider.com - January 9 at 7:56 PM
rttnews.com logoProtalix Provides Review Of 2016 And Outlook For 2017 (NYSEMKT:PLX)
www.rttnews.com - January 9 at 7:56 PM
streetinsider.com logoProtalix BioTherapeutics (PLX) Issues 2016 Review, 2017 Outlook (NYSEMKT:PLX)
www.streetinsider.com - January 9 at 7:56 PM
marketexclusive.com logoProtalix BioTherapeutics, Inc. (NYSEMKT:PLX) Files An 8-K Results of Operations and Financial Condition (NYSEMKT:PLX)
marketexclusive.com - January 9 at 7:56 PM

Social

What is Protalix Biotherapeutics' stock symbol?

Protalix Biotherapeutics trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "PLX."

Where is Protalix Biotherapeutics' stock going? Where will Protalix Biotherapeutics' stock price be in 2017?

3 equities research analysts have issued 1-year target prices for Protalix Biotherapeutics' stock. Their forecasts range from $0.80 to $3.50. On average, they anticipate Protalix Biotherapeutics' stock price to reach $1.77 in the next twelve months.

Who owns Protalix Biotherapeutics stock?

Protalix Biotherapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.48%). Company insiders that own Protalix Biotherapeutics stock include Camber Capital Management Llc and Yossi Maimon.

Who bought Protalix Biotherapeutics stock? Who is buying Protalix Biotherapeutics stock?

Protalix Biotherapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Protalix Biotherapeutics stock in the last two years include Camber Capital Management Llc and Yossi Maimon.

How do I buy Protalix Biotherapeutics stock?

Shares of Protalix Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Protalix Biotherapeutics stock cost?

One share of Protalix Biotherapeutics stock can currently be purchased for approximately $1.08.


Last Updated on 2/21/2017 by MarketBeat.com Staff